Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
Shelsey W. Johnson, Lauren Finlay, Stephen C. Mathai, Ronald H. Goldstein, Bradley A. Maron
Abstract
Inhaled treprostinil was approved recently for interstitial lung disease-pulmonary hypertension; however, efficacy in "real-world" populations is not known. We designed a protocol and report our experience evaluating 10 patients referred for therapy. Misdiagnosis at presentation was common; ultimately, three patients (30%) were prescribed drug. This protocol offers an opportunity to standardize longitudinal assessment of inhaled treprostinil in clinical practice.
Topics & Concepts
MedicineTreprostinilPulmonary hypertensionIntensive care medicineLung diseaseDiseaseLungPulmonary diseaseProtocol (science)Internal medicinePathologyAlternative medicinePulmonary Hypertension Research and TreatmentsHeart Failure Treatment and ManagementChronic Obstructive Pulmonary Disease (COPD) Research